SGO Ovarian Cancer Spotlight

Patients with relapsed, platinum-sensitive <em>BRCA</em>-mutant ovarian cancer experienced a 13.6-month improvement in progression-free survival (PFS) with the PARP inhibitor olaparib versus placebo, according to data reported at the Society of Gynecologic Oncology meeting.

Patients with <em>BRCA</em>-proficient ovarian cancer who were treated with a carboplatin desensitization regimen had an improved overall survival (OS), according to a retrospective analysis reported at the 2017 Society of Gynecologic Oncology Annual Meeting.

Ursula A. Matulonis, MD, discusses results of the phase III NOVA trial showed the PARP inhibitor niraparib demonstrated an improvement in PFS versus placebo as a maintenance therapy for patients with high-grade serous ovarian cancer.

Ursula A. Matulonis, MD, discusses the secondary efficacy results of the NOVA trial, which examines niraparib maintenance therapy for patients with ovarian cancer.

Alon Altman, MD, discusses a study that examined the effects of number of neoadjuvant chemotherapy cycles on patient outcomes.

During the Society for Gynecologic Oncology 48th Annual Meeting in National Harbor, Maryland, Jubilee Brown, MD,&nbsp;offered advice on where to access this counseling and why it is so important for women with ovarian cancer to advocate for genetic testing.&nbsp;

Patients with relapsed, platinum-sensitive, high-grade, ovarian cancer saw activity with the PARP inhibitor rucaparib, according to findings from the ARIEL2 study presented at the Society for Gynecologic Oncology 48th Annual Meeting in National Harbor, Maryland.&nbsp;

Elizabeth Swisher, MD, professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance,&nbsp;discusses next steps regarding treatments for patients with ovarian cancer. Combinations of PARP inhibitors with other DNA repair agents or even with immunotherapy has started to interest researchers.